medigraphic.com
ISSN 1527-3172 (Electronic)

2018, Number 3

<< Back Next >>

MEDICC Review 2018; 20 (3)

HIV-1 Antiretroviral Resistance in Cuba, 2009-2014

Alemán-Campos Y, Kourí-Cardellá V, Pérez-Santos L, Fonseca-Gómez C, Pérez-Avila J, Ortega-González LM, Baños-Morales Y, Álvarez-López A, Correa-Sierra C, Martínez-Montesinos Y, Soto-Brito Y, Limia-León CM, Campos-Díaz J, Caturla-Fernández Y, Alvarez-Gainza D, Pintos-Saavedra Y, Añé-Kourí AL, Joanes-Fiol J

Language: English
References: 39
Page: 15-21
PDF size: 172.74 Kb.


ABSTRACT

INTRODUCTION By the end of 2017, there were more than 28,000 individuals living with HIV in Cuba, over 80% receiving antiretroviral therapy, which dramatically reduces viral replication, improves immune status and decreases risk of transmission. These results could be jeopardized by emergence of HIV-1 drug resistance. In 2009, a test for HIV-1 genotypic resistance was introduced in routine clinical practice in Cuba.
OBJECTIVE Investigate antiretroviral resistance and its relation to subtype distribution in HIV-1 treatment-naïve and previously treated patients in Cuba.
METHODS Resistance and HIV-1 subtype distribution were determined in 342 antiretroviral treatment-naïve patients and 584 previously treated for HIV-1 whose blood specimens were sent to the Pedro Kourí Tropical Medicine Institute during 2009–2014. Transmitted drug resistance was determined using the Calibrated Population Resistance Tool v.6. Drug resistance analysis was conducted using the algorithm Rega v9.1.0.
RESULTS Prevalence of transmitted drug resistance was 11.4%, and 41% of mutated viruses exhibited dual-class resistance to nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor. Overall, 84.9% of patients had ≥1 resistance mutation, 80% had ≥1 nucleoside reverse transcriptase inhibitor mutation, 71.4% had ≥1 nonnucleoside reverse transcriptase inhibitor mutation and 31.7% had ≥1 protease inhibitor mutation. K65R and K101E mutations were signifi cantly more frequent in subtype C, L210W in CRF19_cpx, and M47V/I in CRF BGs (20, 23, 24). Full class resistance to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors and multidrug resistance were detected in 21.2%, 32.4%, 8% and 4.1% of patients, respectively. Average percentage resistance to nucleoside reverse transcriptase inhibitor, protease inhibitor, full class resistance to nucleoside reverse transcriptase inhibitor, protease inhibitor and multidrug resistance increased in patients failing two or more regimens. Nevertheless, after 2011, a declining trend was observed in the frequency of multidrug resistance and full class resistance to nucleoside reverse transcriptase inhibitors and protease inhibitors.
CONCLUSIONS Detected levels of transmitted drug resistance highlight the need for a national surveillance study in treatment-naïve patients. Resistance prevalence is high in previously treated patients but appears to be decreasing over time. The frequency of resistance mutations in recombinant forms of HIV in Cuba needs further study.


REFERENCES

  1. Bertagnolio S, Beanland RL, Jordan MR, Doherty M, Hirnschall AG. The World Health Organization’s response to emerging human Immunodefi ciency virus drug resistance and a call for global action. J Infect Dis. 2017 Dec 1;216(Suppl 9):S801–S4.

  2. UNAIDS. AIDS DATA 2015 [Internet]. Geneva: UNAIDS; 2016 [cited 2017 Sep 16]. 80 p. Available from: http://www.unaids.org/sites/default/ fi les/media_asset/2016-AIDS-data_en.pdf

  3. Aragonés C, Sánchez L, Campos JR, Pérez J. Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba. MEDICC Rev [Internet]. 2011 Apr [cited 2016 Oct 5];13(2):17–23. Available from: http://www.medicc.org/medicc review/pdf.php?lang=en&id=192

  4. Pérez L, Álvarez LP, Carmona R, Aragonés C, Delgado E, Thomson MM, et al. Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS Res Hum Retroviruses [Internet]. 2007 Mar [cited 2017 Sep 9];23(3):407–14. Available from: https://www.liebertpub.com/doi/pdf/10.1089/ aid.2006.0155

  5. Alemán Y, Vinken L, Kourí V, Pérez L, Álvarez A, Abrahantes Y, et al. Performance of an in-house human immunodefi ciency virus type 1 genotyping system for assessment of drug resistance in Cuba. PLoS One [Internet]. 2015 [cited 2017 Sep 16];10(2):e0117176. Available from: http://journals.plos.org/ plosone/article/file?id=10.1371/journal.pone .0117176&type=printable

  6. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol [Internet]. 2013 [cited 2017 Sep 19];30(12):2725–9. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC3840312/pdf/ mst197.pdf

  7. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One [Internet]. 2009 [cited 2017 Sep 16];4(3):e4724. Available from: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC2648874/pdf/pone.00047 24.pdf

  8. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001- 2006) in Portugal. Retrovirology [Internet]. 2008 Feb 1 [cited 2017 Sep 16];5:12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2265747/pdf/1742-4690-5-12.pdf

  9. Hervada Vidal X, Santiago Pérez MI, Vázquez Fernández E, Castillo Salgado C, Loyola Elizondo E, Silva Ayçaguer LC. Epidat 3.0: programa para análisis epidemiológico de datos tabulados. Rev Esp Salud Pública [Internet]. 2004 [cited 2017 Sep 16];78(2):277–80. Available from: https://scielosp.org/pdf/resp/2004.v78n2/277 -280/es. Spanish.

  10. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA [Internet]. 2013 Nov 27 [cited 2018 Jun 17];310(20):2191–4. Available from: https://jamanetwork.com/jour nals/jama/fullarticle/10.1001/jama.2013.28 1053

  11. Pérez L, Kourí V, Alemán Y, Abrahantes Y, Correa C, Aragonés C, et al. Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba. Infect Genet Evol [Internet]. 2013 Jun [cited 2017 Sep 16];16:144–50. Available from: http://www.sciencedirect.com/science/article/pii/ S1567134813000361?via%3Dihub

  12. Kourí V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, et al. High frequency of antiviral drug resistance and non-B subtypes in HIV- 1 patients failing antiviral therapy in Cuba. J Clinical Virol [Internet]. 2012 Dec [cited 2017 Sep 16];55(4):348–55. Available from: http:// www.sciencedirect.com/science/article/pii/ S138665321200323X?via%3Dihub

  13. Machado LY, Blanco M, Dubed M, Díaz HM, Ruiz NM, Váldes N, et al. HIV type 1 genetic diversity in newly diagnosed Cuban patients. AIDS Res Hum Retroviruses [Internet]. 2012 Aug [cited 2017 Sep 18];28(8):956–60. Available from: http://online.liebertpub.com/doi/full/10.1089/ aid.2011.0295

  14. Pérez L, Thomson MM, Bleda MJ, Aragonés C, González Z, Pérez J, et al. HIV Type 1 molecular epidemiology in Cuba: high genetic diversity, frequent mosaicism, and recent expansion of BG intersubtype recombinant forms. AIDS Res Hum Retroviruses [Internet]. 2006 Aug [cited 2017 Sep 18];22(8):724–33. Available from: http://online.liebertpub.com/doi/pdfplus/10 .1089/aid.2006.22.724

  15. Nadai Y, Eyzaguirre LM, Sill A, Cleghorn F, Nolte C, Charurat M, et al. HIV-1 epidemic in the Caribbean is dominated by subtype B. PLoS One [Internet]. 2009 Mar [cited 2017 Sep 18];4(3):e4814. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC2652827/pdf/ pone.0004814.pdf

  16. Vaughan HE, Cane P, Pillay D, Tedder RS. Characterization of HIV type 1 clades in the Caribbean using pol gene sequences. AIDS Res Hum Retroviruses [Internet]. 2003 Oct [cited 2017 Sep 18];19(10):929–32. Available from: http://online.liebertpub.com/doi/pdfplus/ 10.1089/088922203322493120

  17. Thomson MM, Casado G, Posada D, Sierra M, Nájera R. Identifi cation of a novel HIV-1 complex circulating recombinant form (CRF18_cpx) of Central African origin in Cuba. AIDS (London, England). 2005 Jul 22;19(11):1155–63.

  18. Casado G, Thomson MM, Sierra M, Nájera R. Identifi cation of a novel HIV-1 circulating ADG intersubtype recombinant form (CRF19_cpx) in Cuba. J Acquir Immune Defi c Syndr. 2005 Dec 15;40(5):532–7.

  19. Machado LY, Dubed M, Díaz H, Ruiz N, Romay D, Valdés N, et al. Transmitted HIV type 1 drug resistance in newly diagnosed Cuban patients. AIDS Res Hum Retroviruses [Internet]. 2013 Feb [cited 2017 Sep 18];29(2):411–4. Available from: http://online.liebertpub.com/doi/full/10.1089/ aid.2012.0183

  20. Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, et al. Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Hum Retroviruses [Internet]. 2012 Jul;28(7):667–74. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC3380383/pdf/ aid.2010.0355.pdf

  21. Barrow GJ, Hylton-Kong T, Rodríguez N, Yamamura Y, Figueroa JP. HIV-1 drug resistance in treatment-naive, chronically infected patients in Jamaica. Antivir Ther [Internet]. 2013 [cited 2017 Sep 21];18(7):941–4. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC4648998/pdf/ nihms733672.pdf

  22. Escoto-Delgadillo M, Torres-Mendoza BM, Flores-Soto M, Vázquez-Valls E. HIV drug resistance in antiretroviral-naive patients in Mexico after 10 years: is there a difference? AIDS Res Hum Retroviruses. 2016 Dec;22(12):1219–22.

  23. Ávila-Ríos S, García-Morales C, Garrido-Rodríguez D, Tapia-Trejo D, Girón-Callejas AC, Mendizábal- Burastero R, et al. HIV-1 drug resistance surveillance in antiretroviral treatment-naive individuals from a reference hospital in Guatemala, 2010-2013. AIDS Res Hum Retroviruses [Internet]. 2015 Apr [cited 2017 Sep 21];31(4):401–11. Available from: http://online.liebertpub.com/ doi/10.1089/aid.2014.0057

  24. Holguín A, Yebra G, Martín L, de Pineda AT, Ruiz LE, Quezada AY, et al. Transmitted drug-resistance in human immunodefi ciency virus-infected adult population in El Salvador, Central America. Clin Microbiol Infect [Internet]. 2013 Dec [cited 2017 Sep 21];19(12):E523–32. Available from: http://www.sciencedirect.com/science/article/pii/ S1198743X14630913?via%3Dihub

  25. Ávila-Ríos S, García-Morales C, Tapia-Trejo D, Meza RI, Nuñez SM, Parham L, et al. HIV drug resistance surveillance in Honduras after a decade of widespread antiretroviral therapy. PLoS One [Internet]. 2015 [cited 2017 Sep 21];10(11):e0142604. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4641727/pdf/pone.0142604.pdf

  26. Mendoza Y, Castillo Mewa J, Martínez AA, Zaldívar Y, Sosa N, Arteaga G, et al. HIV-1 antiretroviral drug resistance mutations in treatment naive and experienced Panamanian subjects: impact on national use of EFV-based schemes. PLoS One [Internet]. 2016 Apr 27 [cited 2017 Sep 21];11(4):e0154317. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4847863/pdf/pone.0154317.pdf

  27. Jones LR, Moretti F, Calvo AY, Dilernia DA, Manrique JM, Gómez-Carrillo M, et al. Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: subtype, gender, and age issues. AIDS Res Hum Retroviruses [Internet]. 2012 Aug [cited 2017 Sep 26];28(8):949–55. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC3399568/pdf/ aid.2011.0287.pdf

  28. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol [Internet]. 2016 Dec [cited 2017 Sep 29];46:292–07. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC5136505/pdf/ nihms817643.pdf

  29. Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, et al. High prevalence of the K65R mutation in human immunodefi ciency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother [Internet]. 2006 Dec [cited 2017 Sep 26];50(12):4182–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693987/pdf/0714-06.pdf

  30. Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, et al. Impact of human immunodefi ciency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfi navircontaining regimen. Antimicrob Agents Chemother [Internet]. 2006 Jun [cited 2017 Sep 26];50(6):2210–3. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC1479146/ pdf/1447-05.pdf

  31. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodefi ciency virus type 1. J Virol [Internet]. 2009 Feb [cited 2017 Sep 26];83(4):2029–33. Available from: https://www .ncbi.nlm.nih.gov/pmc/articles/PMC2643749/ pdf/1349-08.pdf

  32. World Health Organization. WHO Expert Committee on biological standardization. World Health Organ Tech Rep Ser. 2011(962):1–206.

  33. Kourí V, Khouri R, Alemán Y, Abrahantes Y, Vercauteren J, Pineda-Pena AC, et al. CRF19_cpx is an evolutionary fi t HIV-1 variant strongly associated with rapid progression to AIDS in Cuba. EBioMedicine [Internet]. 2015 Jan 28 [cited 2017 Sep 27];2(3):244–54. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4484819/pdf/main.pdf

  34. Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, et al. 2015 Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med [Internet]. 2015 [cited 2017 Sep 27];23(4):132–41. Available from: http://www .iasusa.org/sites/default/fi les/tam/23-4-132.pdf

  35. Vercauteren J, Theys K, Carvalho AP, Valadas E, Duque LM, Teofi lo E, et al. The demise of multidrug-resistant HIV-1: the national time trend in Portugal. J Antimicrob Chemother [Internet]. 2013 [cited 2017 Sep 29];68(4):911–4. Available from: https://www.ncbi.nlm.nih .gov/pmc/articles/PMC3594492/pdf/dks470.pdf

  36. Vandamme AM, Camacho RJ, Ceccherini- Silberstein F, de Luca A, Palmisano L, Paraskevis D, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev [Internet]. 2011 Apr–Jun [cited 2017 Sep 27];13(2):77–108. Available from: http://www.aidsreviews.com/get .php?x=2011_13_2_077-108.pdf&dp=0

  37. Franzetti M, Violin M, Antinori A, De Luca A, Ceccherini- Silberstein F, Gianotti N, et al. Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003- 2012 decade in Italy. BMC Infect Dis [Internet]. 2014 Jul 18 [cited 2017 Sep 27];14:398. Available from: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4223427/pdf/1471-2334-14-398.pdf

  38. Schmidt D, Kollan C, Fätkenheuer G, Schülter E, Stellbrink HJ, Noah C, et al. Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. PLoS One [Internet]. 2014 Aug 22 [cited 2017 Sep 27];9(8):e104474. Available from: http://journals.plos.org/plosone/ article/file?id=10.1371/journal.pone.0104 474&type=printable

  39. World Health Organization. Surveillance of HIV drug resistance in adults receiving ART (acquired HIV drug resistance). Concept Note [Internet]. Geneva: World Health Organization; 2014 [cited 2017 sept 16]. 50 p. Available from: www.who .int/hiv/pub/drugresistance/acquired_drugresis tance/en/




2020     |     www.medigraphic.com